Pramlintide

Pramlintide is a synthetic analogue of amylin, a hormone co-secreted with insulin by pancreatic beta cells and typically deficient in insulin-treated diabetes. Native human amylin is prone to aggregation, so pramlintide substitutes three proline residues to yield a soluble, stable, injectable peptide. Acting through amylin receptors in the hindbrain, it slows gastric emptying, suppresses inappropriately elevated postprandial glucagon secretion, and enhances satiety. Together these effects blunt post-meal glucose excursions and reduce food intake, complementing insulin's action on fasting and between-meal glucose rather than replacing it.

Pramlintide is an approved prescription medicine supported by randomised controlled trials as a mealtime adjunct to insulin. A 1-year RCT in type 1 diabetes (Ratner et al., Diabet Med 2004) showed modest HbA1c reductions accompanied by weight loss versus insulin alone, with transient nausea the main adverse event. A 1-year RCT in insulin-treated type 2 diabetes (Hollander et al., Diabetes Care 2003) similarly improved long-term glycemic and weight control. It is not indicated as a stand-alone therapy or for weight loss in people without diabetes.

Educational overview only — no dosing instructions in the public hub.

Pramlintide carries a boxed warning for severe, insulin-induced hypoglycemia, which typically occurs within about three hours of injection and can impair driving or operating machinery; insulin doses generally require adjustment when starting. Nausea — usually transient and dose-dependent — is the most common adverse effect. It must be injected separately from insulin (they cannot be mixed) and used only under medical supervision. 'Research use only' material bypasses this oversight and adds identity, purity and dosing risks.

As an approved medicine, legitimate pramlintide comes from a licensed pharmacy under regulatory quality control. Research-grade or grey-market material is not a substitute: it lacks assured identity, purity and concentration, and its use without supervision is especially hazardous given the hypoglycemia warning. A third-party certificate of analysis is a minimum check but cannot replace pharmaceutical-grade sourcing and clinical oversight.

Approved prescription medicine (FDA 2005, marketed as Symlin) indicated as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes; it requires a prescription and medical supervision. It is not an over-the-counter or 'research only' compound, and it is not approved for weight loss in people without diabetes.